KOL Insight Archives | Page 10 of 15 | Report Store

Biomedtracker Q3 2017 Outlook Report

In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

KOL Insight

Biomedtracker Q3 2017 Outlook Report

Datamonitor Healthcare Crohn’s Disease KOL Interviews

Datapack – Pharmaprojects Pharma R&D Annual Review 2017

Chronic Migraine Survey

Non-Alcoholic Steatohepatitis (NASH) Survey

Datamonitor Axial Spondyloarthritis KOL Interviews

Post-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey

Opioids and Chronic Neuropathic Pain Management KOL Interview

Chronic Neuropathic Pain KOL Survey

Abuse-Deterrent Opioids Survey KOL Interview

Non-Small Cell Lung Cancer KOL Interview

Ovarian Cancer Pulse Survey

Post-EASL KOL Insight Interview

Seizure Pulse Survey

Breast Cancer KOL Insight Interview